Common Non-Antibiotic Drugs Sabotage Gut Bacteria That Block Dangerous Infections

The gut microbiome provides a critical barrier against intestinal infections through a process called colonization resistance — commensal bacteria outcompete pathogens for nutrients and space while stimulating host immune defenses. Antibiotics are well-known disruptors of this barrier, but until now, the impact of the far more widely consumed class of non-antibiotic medications has remained largely unexplored.

This study, published in Nature, systematically examined whether non-antibiotic drugs impair colonization resistance against enteropathogens. The researchers first screened 1,197 FDA-approved drugs against five pathogenic Gammaproteobacteria and compared results to previously published data on 43 gut commensals. While antibiotics inhibited both groups equally, commensals were inhibited by roughly three times as many non-antibiotics as pathogens (median 53 vs. 17 drugs). Pathogens' resistance was attributed to their selective outer membrane, high efflux pump gene content, and antibiotic resistance mechanisms — vulnerabilities largely absent in many commensals.

The team developed a novel high-throughput in vitro challenge assay using a defined 20-member synthetic community (Com20) validated against gnotobiotic mouse data. Drug-treated communities were challenged with luminescent S. Typhimurium, enabling rapid quantification of pathogen growth. Of 53 drugs tested, 15 (28%) significantly promoted S. Tm expansion. Key drivers included reduction in total community biomass, selective killing of nutritional competitors such as Bacteroides and Enterococcus species, and metabolic niche liberation. Similar results were obtained with complex stool-derived microbial communities from human donors and for other enteropathogens including Shigella flexneri and Vibrio cholerae.

In mouse colonization models, drugs identified as disruptors in vitro — including the antihistamine terfenadine, the antipsychotic thioridazine, and the antifungal clotrimazole — significantly increased intestinal S. Tm burden. Terfenadine specifically accelerated disease onset and amplified intestinal inflammation, connecting drug-induced microbiome disruption to clinically meaningful infection outcomes. Mechanistic analyses revealed that drug effects on colonization resistance involved a combination of direct commensal inhibition and shifts in metabolic competition, particularly around carbon source utilization.

The study's implications are substantial: millions of people worldwide take non-antibiotic medications daily across diverse therapeutic classes (antihistamines, antipsychotics, antifungals, proton pump inhibitors, and others), and this research identifies these drugs as previously overlooked contributors to enteric infection risk. The authors call for reassessment of drug safety frameworks to include microbiome-mediated infection susceptibility as an outcome.